Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.
TL;DR: This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for H CC.
read more
Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide Chemotherapy is recommended to patients with intermediate or advanced stage cancer However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Recent Advances in miRNA Delivery Systems
Ishani Dasgupta,Anushila Chatterjee +1 more
- 20 Jan 2021
TL;DR: In this paper, the strengths and weaknesses of current state-of-the-art viral and non-viral miRNA delivery systems and how these tools can be exploited to improve the outcomes of miRNA-based therapeutics.
One-Step Formulation of Targeted Aggregation-Induced Emission Dots for Image-Guided Photodynamic Therapy of Cholangiocarcinoma
TL;DR: Different from conventional PSs and previously reported PS-loaded nanostructures, the AIE dots do not suffer from aggregation-caused fluorescence quenching and reduction in reactive oxygen species production when theAIE PS molecules are in an aggregated state.
188
AIE-based cancer theranostics
TL;DR: The combination of AIEgens and different therapy modules provides a great opportunity for image-guided precise cancer treatment, which can efficiently ablate cancer cells both in vitro and in vivo.
167
Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting
TL;DR: This review presents some recent strategies such as immunotherapy, role of cell sex and protein corona in for targeted cancer therapy and also discusses some examples of engineered nanoparticles exploited for active cancer targeting and their limitations and associated toxicity.
144
Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles.
TL;DR: The general characteristics of mesoporous silica nanoparticles – including their physicochemical properties and customizable surfaces – different stimuli that can be used to trigger targeted drug release, biocompatibility and finally, the drawbacks of these types of nanomaterials are summarized.
References
Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy
Qiao-Ling Zhu,Yi Zhou,Min Guan,Xiao-feng Zhou,Shu-di Yang,Yang Liu,Wei-liang Chen,Chun-ge Zhang,Zhi-qiang Yuan,Chun Liu,Aijun Zhu,Xue-nong Zhang +11 more
TL;DR: Results indicated that LDL-SCS-NPs were effective tumor-targeting vectors and that the preparation form may provide a new strategy for co-delivering siRNA and antitumor drugs.
102
Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs
TL;DR: Results indicate HGA nanoparticles can be a potential drug carrier with "double target sites" for liver cancer therapy as indicated by physicochemical characteristics, cellular uptake efficiency, and in vivo fates of HGA conjugates.
102
In Vitro and in Vivo Evaluation of Pectin-Based Nanoparticles for Hepatocellular Carcinoma Drug Chemotherapy
Cui-Yun Yu,Yan-Mei Wang,Na-Mei Li,Ge-Sha Liu,Sa Yang,Guo-Tao Tang,Dong-Xiu He,Xiang-Wen Tan,Hua Wei +8 more
TL;DR: The pectin-based drug delivery systems exhibit size-induced prolonged circulation as well as ASGP receptor-mediated targeting ability to cancer cell lines; therefore, it is a promising platform for the treatment of hepatocellular carcinoma.
101
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
Xue Zhang,Huei Leng Helena Ng,Aiping Lu,Congcong Lin,Limin Zhou,Ge Lin,Yanbo Zhang,Zhijun Yang,Hong Qi Zhang +8 more
TL;DR: The authors reviewed in depth the current challenges facing new drug designs and also outlined novel targeted drug delivery systems (DDS) in the fight against HCC.
101
Glyco-Nanoparticles with Sheddable Saccharide Shells: A Unique and Potent Platform for Hepatoma-Targeting Delivery of Anticancer Drugs
Wei Chen,Wei Chen,Yan Zou,Fenghua Meng,Ru Cheng,Chao Deng,Jan Feijen,Jan Feijen,Zhiyuan Zhong +8 more
TL;DR: These shell-sheddable glyco-nanoparticles are promising for hepatoma-targeting chemotherapy and showed high antitumor activity toward HepG2 cells, which was comparable to free DOX and about 18-fold higher than their reduction-insensitive counterparts.
95